An HBV lookalike that is actually a hollow envelope containing three proteins derived from mammal cells. When it is injected, the body produces protective antibodies against all three of these proteins, offering unprecedented effectiveness.
Since 1982, developing countries have been vaccinating newborns against the hepatitis B virus (HBV). Yet this leading cause of life-threatening liver infection remains a major global health problem directly affecting some two billion people and many more as silent carriers.
Why? Solving this riddle is what enabled the scientists at Israel’s SciGen to pioneer the world’s only commercially available third-generation vaccine against the virus that causes 1.2 million deaths every year.
SciGen CEO Michal Ben-Attar explains that Sci-B-Vac is the most effective and cost-efficient solution to combating HBV anywhere, and is especially needed in Africa where the rates of infection are high.
Almost every newborn in Israel already receives this cutting-edge inoculation on the day of birth, and the formula is registered for use also in Hong Kong, the Philippines, India, Vietnam, Georgia and Central Africa, with approvals in the United States and other countries expected in the near future.